Acute Leukemia of Ambiguous Lineage News

Acute Leukemia of Ambiguous Lineage	Welcome, Profile Billing Logout

||||||||||  dilanubicel (NLA101) / Nohla Therap
Phase classification, Enrollment change, Trial termination:  Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) -  Nov 26, 2018
P1, N=7, Terminated,  Sponsor: Nohla Therapeutics, Inc.
Phase classification: P=N/A --> P1 | N=15 --> 7 | Active, not recruiting --> Terminated

||||||||||  plerixafor / Generic mfg.
Trial completion, Trial completion date:  POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients (clinicaltrials.gov) -  Sep 7, 2018
P1, N=20, Completed,  Sponsor: Seattle Children's Hospital
Phase classification: P=N/A --> P1 | N=15 --> 7 | Active, not recruiting --> Terminated Active, not recruiting --> Completed | Trial completion date: Jul 2017 --> Jun 2016

||||||||||  Erwinase (erwinia L-asparaginase) / Jazz, Ohara Pharma
Enrollment change, Trial withdrawal:  Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies (clinicaltrials.gov) -  Jun 26, 2018
P2, N=0, Withdrawn,  Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed | Trial completion date: Jul 2017 --> Jun 2016 N=20 --> 0 | Not yet recruiting --> Withdrawn

||||||||||  Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz, Nippon Shinyaku
Trial completion, Enrollment change:  Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia (clinicaltrials.gov) -  Jun 3, 2018
P=N/A, N=48, Completed,  Sponsor: Fred Hutchinson Cancer Research Center
N=20 --> 0 | Not yet recruiting --> Withdrawn Active, not recruiting --> Completed | N=90 --> 48

||||||||||  Erwinase (erwinia L-asparaginase) / Jazz, Ohara Pharma
Trial completion date:  Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies (clinicaltrials.gov) -  Mar 14, 2018
P2, N=20, Not yet recruiting,  Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed | N=90 --> 48 Trial completion date: Feb 2021 --> May 2022

||||||||||  Ninlaro (ixazomib) / Takeda
Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date:  Standard Maintenance POMP/D Plus Ixazomib Maintenance Therapy in Adult Patients With Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed Phenotype Acute Leukemia in Complete Remission (CR) (clinicaltrials.gov) -  Feb 15, 2018
P1, N=0, Withdrawn,  Sponsor: Ehab L Atallah
Trial completion date: Feb 2021 --> May 2022 N=18 --> 0 | Recruiting --> Withdrawn | Trial completion date: Mar 2020 --> Feb 2018 | Trial primary completion date: Mar 2018 --> Feb 2018

||||||||||  Erwinase (erwinia L-asparaginase) / Jazz, Ohara Pharma
Trial initiation date, Trial primary completion date:  Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies (clinicaltrials.gov) -  Sep 25, 2017
P2, N=20, Not yet recruiting,  Sponsor: M.D. Anderson Cancer Center
N=18 --> 0 | Recruiting --> Withdrawn | Trial completion date: Mar 2020 --> Feb 2018 | Trial primary completion date: Mar 2018 --> Feb 2018 Initiation date: Dec 2016 --> Feb 2018 | Trial primary completion date: Dec 2019 --> Feb 2021

||||||||||  Ninlaro (ixazomib) / Takeda
Enrollment open:  Standard Maintenance POMP/D Plus Ixazomib Maintenance Therapy in Adult Patients With Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed Phenotype Acute Leukemia in Complete Remission (CR) (clinicaltrials.gov) -  Aug 7, 2017
P1, N=18, Recruiting,  Sponsor: Ehab L Atallah
Initiation date: Dec 2016 --> Feb 2018 | Trial primary completion date: Dec 2019 --> Feb 2021 Not yet recruiting --> Recruiting

||||||||||  Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz, Nippon Shinyaku
Trial primary completion date:  Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia (clinicaltrials.gov) -  Jun 19, 2017
P=N/A, N=90, Active, not recruiting,  Sponsor: Fred Hutchinson Cancer Research Center
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2017 --> Jan 2017

||||||||||  Ninlaro (ixazomib) / Takeda
Trial initiation date:  Standard Maintenance POMP/D Plus Ixazomib Maintenance Therapy in Adult Patients With Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed Phenotype Acute Leukemia in Complete Remission (CR) (clinicaltrials.gov) -  May 5, 2017
P1, N=18, Not yet recruiting,  Sponsor: Ehab L Atallah
Trial primary completion date: Jun 2017 --> Jan 2017 Initiation date: Mar 2017 --> Jun 2017

||||||||||  Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz, Nippon Shinyaku
Enrollment change:  Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia (clinicaltrials.gov) -  Mar 31, 2017
P=N/A, N=90, Active, not recruiting,  Sponsor: Fred Hutchinson Cancer Research Center
Initiation date: Mar 2017 --> Jun 2017 N=46 --> 90

||||||||||  Ninlaro (ixazomib) / Takeda
Trial primary completion date:  Standard Maintenance POMP/D Plus Ixazomib Maintenance Therapy in Adult Patients With Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed Phenotype Acute Leukemia in Complete Remission (CR) (clinicaltrials.gov) -  Mar 1, 2017
P1, N=18, Not yet recruiting,  Sponsor: Ehab L Atallah
N=46 --> 90 Trial primary completion date: Jan 2022 --> Mar 2018

||||||||||  dilanubicel (NLA101) / Nohla Therap
Trial primary completion date:  Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) -  Feb 15, 2017
P=N/A, N=15, Active, not recruiting,  Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Jan 2022 --> Mar 2018 Trial primary completion date: Jun 2017 --> Aug 2018

||||||||||  Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz, Nippon Shinyaku
Enrollment closed, Enrollment change:  Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia (clinicaltrials.gov) -  Jan 12, 2017
P=N/A, N=46, Active, not recruiting,  Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Jun 2017 --> Aug 2018 Recruiting --> Active, not recruiting | N=90 --> 46

||||||||||  Zolinza (vorinostat) / Merck (MSD)
Enrollment change, Trial termination, Trial primary completion date:  Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies (clinicaltrials.gov) -  Jan 6, 2017
P2, N=12, Terminated,  Sponsor: St. Jude Children's Research Hospital
Recruiting --> Active, not recruiting | N=90 --> 46 N=30 --> 12 | Recruiting --> Terminated | Trial primary completion date: Jun 2019 --> Dec 2016; Accrual goals were no longer feasible based on restrictions imposed by the DSMB.

||||||||||  Ninlaro (ixazomib) / Takeda
Trial initiation date, Trial primary completion date:  Standard Maintenance POMP/D Plus Ixazomib Maintenance Therapy in Adult Patients With Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed Phenotype Acute Leukemia in Complete Remission (CR) (clinicaltrials.gov) -  Nov 9, 2016
P1, N=18, Not yet recruiting,  Sponsor: Ehab L Atallah
N=30 --> 12 | Recruiting --> Terminated | Trial primary completion date: Jun 2019 --> Dec 2016; Accrual goals were no longer feasible based on restrictions imposed by the DSMB. Initiation date: Jul 2016 --> Jan 2017 | Trial primary completion date: Jan 2021 --> Jan 2022

||||||||||  dilanubicel (NLA101) / Nohla Therap
Enrollment closed:  Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) -  Nov 2, 2016
P=N/A, N=15, Active, not recruiting,  Sponsor: Fred Hutchinson Cancer Research Center
Initiation date: Jul 2016 --> Jan 2017 | Trial primary completion date: Jan 2021 --> Jan 2022 Recruiting --> Active, not recruiting

||||||||||  Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz, Nippon Shinyaku
Trial primary completion date:  Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia (clinicaltrials.gov) -  Oct 26, 2016
P=N/A, N=90, Recruiting,  Sponsor: Fred Hutchinson Cancer Research Center
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2016 --> Jun 2017

||||||||||  plerixafor / Generic mfg.
Trial primary completion date:  POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients (clinicaltrials.gov) -  Oct 19, 2016
P1, N=21, Active, not recruiting,  Sponsor: Seattle Children's Hospital
Trial primary completion date: Dec 2016 --> Jun 2017 Trial primary completion date: Jul 2014 --> Jul 2017

||||||||||  dilanubicel (NLA101) / Nohla Therap
Trial primary completion date:  Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) -  Sep 27, 2016
P=N/A, N=15, Recruiting,  Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Jul 2014 --> Jul 2017 Trial primary completion date: Dec 2016 --> Jun 2017

||||||||||  Erwinase (erwinia L-asparaginase) / Jazz, Ohara Pharma
Trial initiation date, Trial primary completion date:  Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies (clinicaltrials.gov) -  Sep 20, 2016
P2, N=20, Not yet recruiting,  Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Dec 2016 --> Jun 2017 Initiation date: Jul 2016 --> Dec 2016 | Trial primary completion date: Jul 2019 --> Dec 2019

||||||||||  Ninlaro (ixazomib) / Takeda
Trial initiation date:  Standard Maintenance POMP/D Plus Ixazomib Maintenance Therapy in Adult Patients With Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed Phenotype Acute Leukemia in Complete Remission (CR) (clinicaltrials.gov) -  May 19, 2016
P1, N=18, Not yet recruiting,  Sponsor: Ehab L Atallah
Initiation date: Jul 2016 --> Dec 2016 | Trial primary completion date: Jul 2019 --> Dec 2019 Initiation date: Dec 2015 --> Jul 2016

||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial completion, Enrollment change, Trial primary completion date:  Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) -  May 13, 2016
P2, N=120, Completed,  Sponsor: M.D. Anderson Cancer Center
Initiation date: Dec 2015 --> Jul 2016 Active, not recruiting --> Completed | N=150 --> 120 | Trial primary completion date: Oct 2017 --> May 2016

||||||||||  Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz, Nippon Shinyaku
Trial primary completion date:  Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia (clinicaltrials.gov) -  Apr 29, 2016
P=N/A, N=90, Recruiting,  Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed | N=150 --> 120 | Trial primary completion date: Oct 2017 --> May 2016 Trial primary completion date: Jun 2016 --> Dec 2016

||||||||||  dilanubicel (NLA101) / Nohla Therap
Trial primary completion date:  Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) -  Apr 1, 2016
P=N/A, N=15, Recruiting,  Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Jun 2016 --> Dec 2016 Trial primary completion date: May 2016 --> Dec 2016

||||||||||  Erwinase (erwinia L-asparaginase) / Jazz, Ohara Pharma
New P2 trial:  Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies (clinicaltrials.gov) -  Mar 24, 2016
P2, N=20, Not yet recruiting,  Sponsor: M.D. Anderson Cancer Center

||||||||||  Ninlaro (ixazomib) / Takeda
New P1 trial:  Standard Maintenance POMP/D Plus Ixazomib Maintenance Therapy in Adult Patients With Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed Phenotype Acute Leukemia in Complete Remission (CR) (clinicaltrials.gov) -  Oct 22, 2015
P1, N=18, Not yet recruiting,  Sponsor: Ehab L Atallah

||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Enrollment closed, Trial primary completion date:  Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) -  Aug 12, 2015
P2, N=150, Active, not recruiting,  Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: May 2016 --> Dec 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2016 --> Oct 2017

||||||||||  Zolinza (vorinostat) / Merck (MSD)
Enrollment open:  Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies (clinicaltrials.gov) -  Apr 28, 2015
P2, N=30, Recruiting,  Sponsor: St. Jude Children's Research Hospital
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2016 --> Oct 2017 Not yet recruiting --> Recruiting

||||||||||  Zolinza (vorinostat) / Merck (MSD)
New P2 trial:  Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies (clinicaltrials.gov) -  Apr 17, 2015
P2, N=30, Not yet recruiting,  Sponsor: St. Jude Children's Research Hospital

||||||||||  AT9283 / Otsuka
Trial completion, Enrollment change:  CRUK-CR0708-12: AT9283 in Treating Young Patients With Relapsed or Refractory Acute Leukemia (clinicaltrials.gov) -  Dec 5, 2014
P1/2, N=7, Completed,  Sponsor: Cancer Research UK
Not yet recruiting --> Recruiting Recruiting --> Completed | N=15 --> 7

||||||||||  dilanubicel (NLA101) / Nohla Therap
Trial primary completion date:  Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) -  Jul 30, 2014
P=N/A, N=15, Recruiting,  Sponsor: Fred Hutchinson Cancer Research Center
Recruiting --> Completed | N=15 --> 7 Trial primary completion date: May 2014 --> May 2016

||||||||||  plerixafor / Generic mfg.
Trial primary completion date:  POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients (clinicaltrials.gov) -  Jul 30, 2014
P1, N=21, Active, not recruiting,  Sponsor: Emory University
Trial primary completion date: May 2014 --> May 2016 Trial primary completion date: Dec 2013 --> Jul 2014

||||||||||  Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Trial completion, Enrollment change, Epigenetic controller:  Entinostat and Clofarabine in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Poor-Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia (clinicaltrials.gov) -  Jul 17, 2014
P1, N=27, Completed,  Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2013 --> Jul 2014 Active, not recruiting --> Completed | N=34 --> 27

||||||||||  obatoclax (GX 15-070) / Teva
Enrollment change, Combination therapy:  Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia (clinicaltrials.gov) -  Apr 29, 2014
P1, N=22, Terminated,  Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | N=34 --> 27 N=52 --> 22

||||||||||  MK-2206 / Merck (MSD)
Enrollment change:  MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia (clinicaltrials.gov) -  Apr 27, 2014
P1, N=45, Completed,  Sponsor: National Cancer Institute (NCI)
N=52 --> 22 N=96 --> 45

||||||||||  Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Enrollment closed, Epigenetic controller:  Entinostat and Clofarabine in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Poor-Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia (clinicaltrials.gov) -  Apr 22, 2014
P1, N=34, Active, not recruiting,  Sponsor: National Cancer Institute (NCI)
N=96 --> 45 Recruiting --> Active, not recruiting

||||||||||  plerixafor / Generic mfg.
Enrollment closed:  POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients (clinicaltrials.gov) -  Nov 17, 2013
P1, N=21, Active, not recruiting,  Sponsor: Emory University
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting

||||||||||  MK-2206 / Merck (MSD)
Trial completion:  MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia (clinicaltrials.gov) -  Sep 26, 2013
P1, N=45, Completed,  Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed

||||||||||  obatoclax (GX 15-070) / Teva
Trial termination, Combination therapy:  Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia (clinicaltrials.gov) -  Jun 30, 2013
P1, N=22, Terminated,  Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Terminated

||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Enrollment change:  Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) -  Jun 13, 2013
P2, N=150, Recruiting,  Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Terminated N=100 --> 150

||||||||||  Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz, Nippon Shinyaku
Enrollment open:  Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia (clinicaltrials.gov) -  May 2, 2013
P=N/A, N=90, Recruiting,  Sponsor: Fred Hutchinson Cancer Research Center
N=100 --> 150 Not yet recruiting --> Recruiting

||||||||||  Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Enrollment change, Epigenetic controller:  Entinostat and Clofarabine in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Poor-Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia (clinicaltrials.gov) -  Apr 15, 2013
P1, N=34, Active, not recruiting,  Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting N=46 --> 34

||||||||||  dilanubicel (NLA101) / Nohla Therap
Enrollment open:  Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) -  Dec 16, 2012
P=N/A, N=15, Recruiting,  Sponsor: Fred Hutchinson Cancer Research Center
N=46 --> 34 Not yet recruiting --> Recruiting

||||||||||  AT9283 / Otsuka
Enrollment open:  CRUK-CR0708-12: AT9283 in Treating Young Patients With Relapsed or Refractory Acute Leukemia (clinicaltrials.gov) -  Feb 5, 2012
P1/2, N=15, Recruiting,  Sponsor: Cancer Research UK
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting

||||||||||  AT9283 / Otsuka
New P1/2 trial:  CRUK-CR0708-12: AT9283 in Treating Young Patients With Relapsed or Refractory Acute Leukemia (clinicaltrials.gov) -  Sep 7, 2011
P1/2, N=15, Recruiting,  Sponsor: Cancer Research UK



	Diseases Companies Products Productz Mechanisms of Action Sites